6th Pharmaceutical Pricing & Reimbursement

FEATURED WORKSHOP SESSION:

STATE RUN DRUG & DEVICE ASSESSMENT PROGRAMS
State-Wide Health Technology Assessment Programs used to Ensure Medical Treatment Efficacy: Program Overviews and Next Steps

WORKSHOP LEADERS:
Rob Clark
Senior Director, Corporate State Government Affairs
MEDTRONIC

William E. Struyk
Region Director, State Government Affairs
JOHNSON & JOHNSON

TOPICS TO BE ADDRESSED:

- The Current Healthcare Reform Bill: Industry Considerations for Pricing and Reimbursement Strategies

- Health Technology Assessment Programs

- Legislative changes to the Drug Rebate Program: Accurately Forecasting Rebate Liability

- Ultra-Orphan Product Pricing

- The Sustainable Growth Rate (SGR): Implications for Physician Payment

- Federal Reform on the State Level and Policy Changes

- Using Health Outcomes Studies to Demonstrate Value & Support for Pricing & Reimbursement

- Evaluating the Advantages and Challenges of Outcomes-Based Risk Sharing Programs

- How to Maximize Specialty Pricing and Distribution Strategies

- Comparative Effectiveness Research to Determine the Clinical & Economic Value of a Product to a Payor

- Maximizing Oncology Pricing and Distribution Strategies

*Pres. Obama signed the Health Care and Education Reconciliation Act of 2010 - The combined package spends $940 billion to expand health care coverage to 32 million Americans. Changes that will take place within six months of enactment include banning discrimination against children with pre-existing conditions, banning lifetime insurance caps, banning rescissions when people get sick and beginning to close the “doughnut” hole for Medicare prescriptions drug benefits.